The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword.
COVID-19
Chemotherapy resistance
Cytokine storm
Pathogenesis
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
17
07
2021
accepted:
01
10
2021
pubmed:
18
10
2021
medline:
19
1
2022
entrez:
17
10
2021
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-COV2) was first detected in Wuhan, China in December, 2019. The emerging virus causes a respiratory illness, that can trigger a cytokine storm in the body. Cytokine storm in patient's body is associated with severe forms of disease. It is one of the main complications of coronavirus disease-2019 (COVID-19), in which immune cells play a major role. Studies have shown immune cells in the tumor environment can be effective to induce resistance to chemotherapy in cancer patients. Therefore, considering the role of immune cells to induce cytokine storm in COVID-19 patients, and their role to cause resistance to chemotherapy, they are effective on disease progression and creation of severe form of disease. By examining the signaling pathways and inducing resistance to chemotherapy in tumor cells and the cells affect them, it is possible to prevent the occurrence of severe forms of the disease in cancer patients with COVID-19; it is applicable using target therapy and other subsequent treatment strategies.
Identifiants
pubmed: 34657251
doi: 10.1007/s11033-021-06800-4
pii: 10.1007/s11033-021-06800-4
pmc: PMC8520341
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
605-615Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Lasers Med Sci. 2021 Dec;36(9):1781-1789
pubmed: 33474663
Nat Commun. 2020 Aug 6;11(1):3924
pubmed: 32764665
Onco Targets Ther. 2019 Apr 18;12:3051-3063
pubmed: 31114248
J Exp Clin Cancer Res. 2019 Nov 27;38(1):475
pubmed: 31771611
Sci Rep. 2016 Apr 19;6:24675
pubmed: 27091625
Int J Mol Sci. 2019 Nov 20;20(23):
pubmed: 31756952
Front Immunol. 2018 Mar 08;9:470
pubmed: 29568299
Oncotarget. 2017 Feb 7;8(6):9961-9973
pubmed: 28035069
J Mol Cell Cardiol. 2019 Feb;127:105-114
pubmed: 30553885
Cancer Res Treat. 2019 Jan;51(1):194-210
pubmed: 29690750
Onco Targets Ther. 2017 Jun 29;10:3215-3224
pubmed: 28721072
Cancer Res. 2017 Sep 1;77(17):4697-4709
pubmed: 28652246
Arthritis Rheumatol. 2020 Jul;72(7):1059-1063
pubmed: 32293098
Pharmaceutics. 2020 Dec 09;12(12):
pubmed: 33316872
Future Sci OA. 2021 Apr 20;7(7):FSO712
pubmed: 34254030
Oncotarget. 2017 Feb 14;8(7):11530-11543
pubmed: 28086235
Cancer Metastasis Rev. 2006 Sep;25(3):387-408
pubmed: 17043764
Apoptosis. 2008 May;13(5):681-92
pubmed: 18392938
Inflamm Res. 2020 Sep;69(9):825-839
pubmed: 32529477
J Inflamm Res. 2021 Apr 16;14:1487-1510
pubmed: 33889008
Mol Cancer. 2017 Mar 29;16(1):70
pubmed: 28356111
Onco Targets Ther. 2017 Sep 25;10:4711-4717
pubmed: 29026319
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Clin Rheumatol. 2019 Nov;38(11):3211-3215
pubmed: 31352646
Theranostics. 2019 Jul 9;9(18):5166-5182
pubmed: 31410208
Echocardiography. 2020 Jan;37(1):124-131
pubmed: 31841238
Biochem J. 2007 Jul 15;405(2):251-9
pubmed: 17407446
Cancers (Basel). 2020 May 19;12(5):
pubmed: 32438640
Cell Cycle. 2016 Sep 16;15(18):2398-404
pubmed: 27315462
Am J Cancer Res. 2021 Feb 01;11(2):479-494
pubmed: 33575082
JAMA Intern Med. 2020 Sep 1;180(9):1152-1154
pubmed: 32602883
Adv Enzyme Regul. 2007;47:64-103
pubmed: 17382374
Front Pharmacol. 2021 Mar 15;12:628690
pubmed: 33790792
Inflammopharmacology. 2019 Jun;27(3):627-638
pubmed: 30244296
J Neuroinflammation. 2016 Apr 13;13(1):78
pubmed: 27075886
Oncotarget. 2017 Jun 27;8(46):80358-80372
pubmed: 29113309
Cancers (Basel). 2019 Aug 15;11(8):
pubmed: 31443242
Mol Cancer Ther. 2015 Jun;14(6):1385-94
pubmed: 25887886
Acta Pharmacol Sin. 2008 Nov;29(11):1275-88
pubmed: 18954521
Cancer Cell. 2009 Feb 3;15(2):79-80
pubmed: 19185839
Arthritis Rheum. 2013 Dec;65(12):3063-72
pubmed: 24022618
Oncol Lett. 2017 Mar;13(3):1856-1860
pubmed: 28454334
Anesth Pain Med. 2019 Feb 24;9(1):e83967
pubmed: 30881906
PLoS One. 2017 Sep 15;12(9):e0183662
pubmed: 28915246
Oncotarget. 2016 Sep 20;7(38):61183-61198
pubmed: 27533463
Signal Transduct Target Ther. 2017 Aug 18;2:17036
pubmed: 29263924
Nat Commun. 2017 Jun 19;8:15870
pubmed: 28627514
J Thromb Thrombolysis. 2021 Feb;51(2):446-453
pubmed: 33151461
Biosci Rep. 2017 Jun 21;37(3):
pubmed: 28450497
Mol Cancer Ther. 2017 Oct;16(10):2234-2245
pubmed: 28729401
Dermatol Ther. 2021 Jan;34(1):e14438
pubmed: 33085149
Echocardiography. 2021 Jun;38(6):1074-1076
pubmed: 33973675
Cells. 2020 Jan 15;9(1):
pubmed: 31952344
Int J Mol Sci. 2018 Aug 16;19(8):
pubmed: 30115896
Mol Cancer. 2018 Feb 19;17(1):47
pubmed: 29455640
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Int J Oncol. 2019 Sep;55(3):684-696
pubmed: 31322183
Mol Oncol. 2018 Mar;12(3):305-321
pubmed: 29215776
J Cancer Res Clin Oncol. 2015 Oct;141(10):1697-713
pubmed: 25270087
Breast Cancer Res. 2008;10(6):R105
pubmed: 19087274
Am J Respir Cell Mol Biol. 2011 Apr;44(4):571-81
pubmed: 20581097
Biochem Biophys Res Commun. 2017 Aug 26;490(3):780-785
pubmed: 28645612
Clin Transl Med. 2018 Sep 3;7(1):27
pubmed: 30175384
Am J Cancer Res. 2015 Feb 15;5(3):1169-79
pubmed: 26045995
Cancer Res. 2019 Mar 15;79(6):1165-1177
pubmed: 30674535
Ann Transl Med. 2020 Jul;8(14):856
pubmed: 32793700
J Cosmet Dermatol. 2021 May;20(5):1411-1415
pubmed: 33565223
J Bone Oncol. 2020 Jun 01;23:100299
pubmed: 32566472
Cell Death Dis. 2018 Aug 29;9(9):880
pubmed: 30158589
J Cell Physiol. 2015 Aug;230(8):1883-94
pubmed: 25546229
J Cancer Prev. 2020 Sep 30;25(3):152-163
pubmed: 33033709
Cell Rep. 2012 Sep 27;2(3):478-87
pubmed: 22939982
J Clin Med. 2019 May 09;8(5):
pubmed: 31075939
J Clin Invest. 2020 Jul 1;130(7):3560-3575
pubmed: 32229721
Br J Haematol. 2020 Jul;190(1):e9-e11
pubmed: 32369612
Mol Cancer. 2011 Dec 15;10:150
pubmed: 22171994
Echocardiography. 2020 Mar;37(3):469-471
pubmed: 32049387
Mol Biol Rep. 2020 Jul;47(7):5503-5509
pubmed: 32572734
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Clin Cancer Res. 2013 Aug 1;19(15):4046-57
pubmed: 23723299
Front Cell Dev Biol. 2018 Oct 09;6:131
pubmed: 30356656
PLoS One. 2013 Sep 12;8(9):e75489
pubmed: 24069422
Oncotarget. 2016 Mar 1;7(9):10557-67
pubmed: 26859684
PLoS Comput Biol. 2016 Jun 02;12(6):e1004924
pubmed: 27253373
Nat Commun. 2015 Aug 11;6:7847
pubmed: 26260587
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Rev Med Virol. 2020 Nov;30(6):1-9
pubmed: 32845568
Cancer Res. 2018 Apr 1;78(7):1700-1712
pubmed: 29363544
Oncotarget. 2016 Dec 20;7(51):85021-85032
pubmed: 27829223
Intern Emerg Med. 2021 Nov;16(8):2181-2191
pubmed: 33837906
Oncotarget. 2014 Dec 30;5(24):12916-35
pubmed: 25428915
Front Endocrinol (Lausanne). 2019 Jul 12;10:471
pubmed: 31354634
J Cell Sci. 2002 Nov 15;115(Pt 22):4227-36
pubmed: 12376555
J Cancer. 2018 Oct 31;9(23):4430-4439
pubmed: 30519349